Summary A member of the high molecular weight glycoproteins of human milk and breast cancer was isolated from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1. 
Murine monoclonal antibody 3E1.2, produced by a hybridoma derived from spleen cells of a mouse immunised with a human primary breast carcinoma, has demonstrated selective reactivity with >90% breast carcinoma tissues and limited reactivity with normal breast tissue and other normal secretory epithelium (Stacker et al., 1985) . The antigen defined by 3E1.2 (called mammary serum antigen or MSA) has also been detected in serum, with elevated levels in a high proportion of patients with localised (-75%) or disseminated (-90%) breast cancer . Studies have shown that levels of MSA are useful for monitoring patients with breast cancer; the antibody has also been used to localise metastases in axillary lymph nodes in patients with breast cancer by immunoscintigraphy (Thompson et al., 1984) .
A number of monoclonal antibodies have been described which react with breast cancer associated antigens and have tissue distribution similar to 3E1.2 Ellis et al., 1984; Hilkens et al., 1984; Kufe et al., 1984; Papsidero et al., 1983) . Most of these antibodies have been shown to detect circulating antigens in the serum of patients with advanced breast cancer but the detection in localised breast cancer has been poor (Burchell et al., 1984; Dhokia et al., 1986; Hayes et al., 1985; Hilkens et al., 1984 Hilkens et al., , 1986 Kufe et al., 1984) . All of these monoclonal antibodies define antigens which have common biochemical characteristics:
glycoproteins of high molecular weight (M, >300,000 by SDS-PAGE) with extensive 0-linked carbohydrate side chains, i.e. mucin-like. In addition these monoclonal antibodies also react with human milk and human milk-fat globule membrane (HMFGM) and some antibodies have been shown to react with the PAS-O glycoprotein from human milk which is the one human tumour associated mucin glycoprotein bearing human tumour associated epitopes (Shimizu et al., 1982; Ormerod et al., 1985) . The Correspondence: I.F.C. McKenzie.
PAS-0 component has also been referred to as EMA (epithelial membrane antigen) complex (Ormerod et al., 1983 (Ormerod et al., , 1985 and recently popularised as human PEM (polymorphic epithelial mucin) because of the genetic polymorphism exhibited.
The purpose of this study was to isolate 3E1.2 antigen (MSA) from the serum, ascitic fluid and breast cancer tissue of patients with breast cancer, define its biochemical structure and investigate its relationship to previously described breast cancer associated antigens. MSA was found to be a novel variant of the high molecular weight glycoproteins of human breast cancer, as monoclonal antibody 3E1.2 does not react with components of human milk.
Materials and methods

Monoclonal antibodies
Mouse monoclonal antibody 3E1.2 (anti-MSA) was used to immunopurify MSA in this study. The antibody is a pentameric 1gM raised against human breast cancer cells derived from a primary carcinoma of the breast (Stacker et al., 1985) . Control antibodies used were 5C1 (anti-carcinoma of the colon), 3B1l1C8 (anti-carcinoma of the lung) and 676 (anti-human CD8) (produced in our laboratory). All of these antibodies were of the p heavy chain isotype and were made in our laboratory. The following anti-human milk fat globule membrane antibodies were employed: HMFG-1 (IgGl), kindly supplied by Dr J. Taylor-Papadimitriou, ICRF, London (Taylor-Papadimitriou et al., 1981) , BC2 (IgGI), BC3 (IgM), 41.3 (IgM), 4B6.1 (IgM) (produced in our laboratory) and DF3 (IgGl) obtained from a CA 15-3 IRMA kit (Centocor, Malvern, PA, USA), supplied by the Australian Atomic Energy Commission (Kufe et al., 1984) . The IgM monoclonal antibodies were purified from ascitic fluid by lipid extraction using freon (1,1,2-trichlorotrifluorethane, Fluka AG, Buchs, Switzerland) and dialysis Br. J. Cancer (1989), 59, 544-553 kl--", The Macmillan Press Ltd., 1989 against 5 mM Tris-HCl pH 7.4 at 4°C. The precipitate formed was collected by centrifugation at 800g for 30 min and resuspended in phosphate buffered saline (PBS), pH 7.4. The IgG antibodies were purified on protein A-sepharose (Pharmacia Inc., Piscataway, NJ) as described (Ey et al., 1978) . Purified antibodies (3E1.2 and 4B6.1) were covalently bound to cyanogen bromide activated Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden) at about 3 mg ml-1 of swollen beads.
Collection of serum samples, ascitic fluid and breast carcinoma tissue Serum was obtained from normal subjects and from patients with metastatic breast cancer, and stored at -70°C. Ascitic fluid and primary breast carcinoma tissue were also obtained from one patient who had high circulating MSA level (>10,000IU). Ascitic fluid was centrifuged at 10,000g for 10min to pellet cell debris and the supernatant stored at -700C.
Preparation and deglycosylation of human milk fat globule membrane (HMFGM) and purification of the milk mucin Crude HMFGM were prepared from fresh human milk (Jarasch et al., 1977) after ultracentrifugation at l00,OOOg for 1.5h at 4°C using Beckman L8-70 with an SW-28 rotor. The pellet was resuspended in 0.3M sucrose, 70mM KCI2, 2 mm MgCl2, 1Omm Tris-HCl buffer pH 7.4 and stored at -70°C. 0-linked carbohydrate residues were removed from the HMFGM glycoproteins by treatment with trifluoromethanesulfonic acid (TFMSA) for 1 h at RT (room temperature) to produce deglycosylated HMFGM (Edge et al., 1981) . The milk mucin was purified from human skimmed milk by passage through a 4B6.1 affinity column followed by size exclusion chromatography ; the high molecular weight fractions eluted were pooled and designated PAS-O (Shimizu et al., 1982) .
Serological assays MSA activity in samples was determined by a competitive enzyme immunoassay (MSA inhibition assay) (Stacker et al., 1987 column and washed extensively with PBS pH 7.6 at 4°C. Bound MSA was eluted in 1 ml fractions with 1% diethylamine, pH 11.8 at room temperature (RT) and neutralised with 1 M Tris-HCl pH 7.0. Samples were then freeze dried and tested for activity using the inhibition assay. MSA was also isolated from serum on wheat germ agglutinin (WGA)-Sepharose 6MB, followed by elution with 0.7mgml-1 Nacetyl glucosamine as described elsewhere (Gurd et al., 1974) .
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting Samples were analysed by SDS-PAGE (Laemmli, 1970) and after electrophoresis gels were stained with either 0.2% Coomassie blue or 0.25% Croci en scarlet followed by extensive destaining (7% acetic acid for Coomassie blue, 7% acetic acid/12% ethanol for Croci en scarlet) or by Periodic acid-Schiff (PAS)-silver stain technique (Dubray et al., 1982) . Gels were then dried under vacuum, and autoradiographed at -70°C using XAR-5 film (Eastman Kodak, Rochester, NY, USA) and intensifying screens (DuPont, Wilmington, DE, USA). Molecular weight markers used were: 200,000 myosin, 116,000 fl-galactosidase, 92,500 phosphorylase b, 66,000 bovine serum albumin, 43,000 ovalbumin (Biorad Laboratories). Monoclonal antibody immunoblotting analysis of samples (under reducing conditions) after fractionation by SDS-PAGE was performed as described elsewhere (Towbin et al., 1979) . Nitrocellulose membranes (Schleicher and Schuell, Dassel, FRG) were reacted with a 1/5 dilution of tissue culture supernatant containing the antibody and developed using sheep anti-mouse immunoglobulin conjugated to horseradish peroxidase (Amersham). Alternatively, blotted proteins were reacted with 200,000 c.p.m. of radiolabelled DF3, BC3 or control antibody and then autoradiographed.
Radiolabelling of proteins and solid phase immunoprecipitation technique (SPIT)
Iodination of purified MSA with Na 1251 (Amersham International, Amersham, UK) was catalysed using lodobeads (Pierce Chemical Co. Inc., Rockford, IL, USA) (Markwell, 1982) . Crude HMFGM was radiolabelled, solubilised in 2% (w/w) sodium deoxylate, 8 M urea and 1% (v/v) 2-mercaptoethanol for 30min at 37°C, then centrifuged at 10,OOOg for 20min. Free 1251 was removed from the supernatant by chromatography on Sephadex G-25 (PD-10, Pharmacia) equilibrated in Tris-HCl buffer (pH 8.0) containing 100mM NaCl and 10mM sodium deoxycholate. In the SPIT assay, purified monoclonal antibodies were coated at 40 yg ml-1, in a carbonate buffer pH 9.6, to 96-well flexible PVC plates (Costar, Cambridge, MA, USA) for 2 h at 37°C. Excess antibody was removed by washing with PBS/0.05% Tween 20 and non-specific binding sites blocked by incubation with 2% normal mouse serum (NMS)/2% bovine serum albumin (BSA)/PBS for 2 h at 37°C. After washing, iodinated affinity purified MSA in 2% NMS/2% BSA/PBS pH 7.6 was added to the wells (-750,000 c.p.m. per well) and incubated overnight at 4°C. Following this, the solid phase was washed extensively with PBS/0.05% Tween 20. Plates were dried, cut, and counted in a gamma-counter. In some cases, radiolabelled MSA was eluted from the solid phase with 8 M urea/0.0625 M Tris/2.3% SDS/50 mM DTT (Dithiothreitol) and analysed by SDS-PAGE as described.
Periodate and neuraminidase (NE) treatment Periodate oxidation was performed by treating ZR75 membrane preparation (MSA+), which has been coated on microtitre plates . Sodium metaperiodate (Ajax Chemicals, Australia) was added at concentrations ranging from 10 to 100mm, in a buffer of 50mM sodium acetate, pH4.5 for 2h at 4°C. Wells were treated with 1% BSA to block non-specific binding sites, and then tested for antibody 3E1.2 binding by ELISA as described before. The immunoperoxidase assays on sections of formalin fixed breast cancer tissues were performed as previously described (Stacker et al., 1985) . The tissue sections which were subjected to neuraminidase treatment were incubated with 1 IU per slide neuraminidase (from Vibrio cholerae, Institut Behring) for 2h at 37°C, after they had been treated with 0.5% H202 in PBS to remove endogenous peroxidase activity. After neuraminidase treatment, the slides were washed, exposed to the monoclonal antibody (1:10 dilution of tissue culture supernatant of 1:1,000 diluted mouse ascites fluid) and processed. (Figure 1) , and its activity determined by the inhibition assay. Although MSA stained poorly with Coomassie blue (Figure la) , it stained well with PAS-silver stain (Figure lb) . Virtually all of the initial MSA activity was recovered from the antibody column in a single broad peak; the absence of extraneous bands in SDS-PAGE S indicates stacking gel. Differences in the intensity of the high molecular weight bands between serum and affinity purified MSA in the PAS-silver stain could be accounted for by the difference in the amount loaded on to the gel. analysis (Figure 1 ) indicated that the preparation was pure. This does not eliminate, however, the possibility that there may be contaminants with the same electrophoretic mobility as MSA. The fractions containing purified material were pooled, radiolabelled and assayed by a solid phase immunoprecipitation technique (SPIT) for activity with 3E1.2 and other isotype matched control antibodies. The 3E1.2 monoclonal antibody immune precipitated more than 20 times the amount of radiolabelled antigen precipitated by the control antibodies. When these samples were eluted with 8M urea/ SDS sample buffer from the coated wells and analysed by SDS-PAGE, two discrete bands with Mr values of 300,000-400,000 were observed (Figure 2a) . Identical patterns were seen under reducing and non-reducing conditions, indicating that the two molecules are not covalently linked. The 3E1.2 antibody was also reactive with the immunoadsorbent purified MSA from serum on immunoblots and Figure 2b (tracks D and E) show the reaction of antibody 3E1.2 with the dominant Mr300,000-400,000 bands of the MSA. (Figure 3, patient D) . This immunoblotting experiment demonstrates that the epitope for 3E1.2 is expressed on both Mr species (Figure 3, patients B and C) . A smaller molecular weight species (Mr70,000-100,000) was also detected in some patients on immunoblot of SDS-PAGE-separated serum (Figures 2b and 3) , indicating that the lower molecular weight material also expresses an epitope reactive with antibody 3E1.2 and may share a functional as well as immunological relationship with the high molecular weight material on which many cancerrelated determinants are expressed later. However, the absence of the low molecular weight species (Mr 70,000-100,000) in the immunopurified MSA on immunoblot (Figure 2b ) suggests that they do not bind to 3E1.2 immunoaffinity column to any significant extent (Figure 3 , tracks D and E); the reason of which is not entirely clear but it may indicate that the low molecular weight species are not exposed in the native state, in the absence of SDS but this is not proved.
The ascites and ENM preparations from breast carcinoma tissue of a patient with advanced breast cancer who had a high circulating MSA level (>10,000) was analysed by the inhibition assay. Both the ascites and ENM preparations and strong inhibitory activity (8,000 and 5,000IU respectively). The nature of the 3E1.2 defined antigen (MSA) in serum, ascites and ENM preparations of the same patient was examined by Western blot analysis with 3E1.2 antibody probe. As shown in Figure 2b , the 3E1.2 defined antigen (MSA) was identified as a diffusely migrating band of similar high apparent molecular weight (>300,000), irrespective of the source of the antigen in the same patient. The pattern was reproducible on repeated testing with specimens from other patients and is similar to that obtained with immunoadsorbent purified MSA from serum when probed with 3E1.2 antibody (Figure 2b) . A faint band of 3E1.2 reactive material of Mr-220,000 was also noted in the ENM preparation from breast carcinoma tissue.
Clearly, 3E1.2 defined antigen (MSA) present in detergent solubilised tumour membrane preparations were similar to 3E1.2 defined antigen present in serum and ascites of the same patient. Similar high molecular weight components reactive with 3EI.2 antibody in normal sera were not easily identified by immunoblotting (data not shown). Figure 2 Analysis of MSA by SPIT assay, SDS-PAGE, and immunoblots. In (a) fractions eluted from the immunoaffinity column that contained MSA activity were pooled, radiolabelled and used for SPIT assay using various antibodies. (Figure 6b) . Antibody 3E1.2 showed no detectable reactivity with any components of human milk (Figure 6b , track A), but antibody 41.3 (anti-HMFG) detecting the high molecular weight glycoprotein gave a clear reactivity with these components (Figure 6b, track B) . To determine if the epitope detected by 3E1.2 was masked by carbohydrate on HMFGM, deglycosylated HMFGM glycoproteins were prepared and tested in the solid phase binding assay. 3E1.2 was non-reactive with both glycosylated HMFGM and deglycosylated HMFGM; in contrast, antibody BC3 (IgM), known to detect a high molecular weight glycoprotein of HMFGM, bound to both glycosylated and deglycosylated HMFGM (full data not shown). Similarly, the reactivity of antibody HMFG-1 with both glycosylated and deglycosylated HMFGM had been previously noted (Burchell et al., a 1 E 1987 . , , . . * i v . . ( Figure 7b) . MSA was also subjected to digestion with a large excess of trypsin, Staphylococcus aureus V8 protease and thermolysin (250 yugml-1) for 16h at 37°C with identical results (data not shown). To investigate the relationship between MSA and the high molecular weight glycoprotein of human milk (PAS-O), proteolytic digestion was performed using the enzymes pronase and subtilisin on gel purified MSA and PAS-O (Figure 7b ). The subtilisin digest of MSA contained a cluster of glycopeptide bands of M, values 60,000-100,000. These bands were absent in the corresponding PAS-O channel. However, it cannot be confidently concluded that this disparity is due solely to differences in the polypeptide backbones of the two structures since differential glycosylation might also contribute to the different patterns of proteolytic digestion of MSA and PAS-O.
Multiple epitope expression on MSA MSA eluted from a 3EI.2 immunoaffinity column was tested for its reactivity with a number of monoclonal antibodies which detect epitopes known to be expressed on PAS-O of HMFGM and the high molecular weight glycoproteins seen in the serum of patients with breast cancer. Antibodies DF3 and BC3 (anti-HMFG) were tested for their reactivity on MSA by immunoblotting (Figure 8 ). Both antibodies reacted with MSA, indicating that their epitopes are present on some or all 3E1.2+ molecules. Antibodies 41.3 and 4B6.1, directed to glycoprotein PAS-O of human milk also reacted with MSA (data not shown). These studies indicate that the MSA molecule contains a significant number of epitopes in common with PAS-O and the high molecular weight glycoprotein previously described in breast cancer.
As shown in Table I , using a sandwich immunoassay, when hybridoma ascitic fluids were adsorbed to the wells of PVC plates and then treated with MSA, purified from serum, there was subsequent significant binding of 125J1 labelled 3E1.2 antibody only in wells coated with 3E1.2 and BC3 antibodies but not in wells coated with control antibody (Stacker et al., 1985; Tjandra et al., 1988) . Studies have shown that MSA is elevated in the sera of a high proportion of patients with breast cancer, compared to normal individuals, and that the levels are useful for monitoring patients with breast cancer (Stacker et al., 1987; Tjandra et al., 1988) . Using the sera from patients with advanced breast cancer as a source of antigen, MSA was isolated using immunoaffinity chromatography and a solid phase immunoprecipitation technique. Subsequent SDS-PAGE and immunoblotting analysis showed the antigenic determinants for antibody 3E1.2 reside on heterogeneous molecules of Mr300,000-400,000. These molecules stained pQorly with Coomassie blue but stained well in a PAS-silver stain and they bound the lectin WGA (data not shown), indicating the glycoprotein nature of MSA. The high molecular weight of MSA was confirmed by gel filtration chromatography of material eluted from a 3EI.2 affinity column and a WGA affinity column. There was a difference between the native (Mr=0.7-2.0 x 106) and apparent '(Mr 300,000) molecular weights. Whether the larger molecules arise by spontaneous association of monomers or through link proteins is not clear (Wesley et al., 1985; Pearson et al., 1981) . The results of the immunoblotting tests indicate that 3E1.2 defined antigen (MSA) from serum, ascites or breast carcinoma of the same patient displayed similar mobility in SDS-PAGE gels. In addition, the antigens purified from different sources had strong inhibitory activity when tested in the MSA inhibition assay. It appears that 3E1.2 defined antigen (MSA) can be released from breast carcinoma to the circulation and also locally into the ascites. The level of MSA in the circulation has been shown to depend on the tumour burden and tumour grade but is also dependent on some other factors as yet unidentified, as some cases of carcinoma in situ had elevated circulating MSA level Hare et al., 1988) .
Studies by other workers have also demonstrated the existence of high molecular weight glycoproteins on human breast cancer cells (Ashall et al., 1982; Burchell et al., 1984; Linsley et al., 1986; Ormerod et al., 1983; Papsidero et al., 1984a; Price et al., 1985; Sekine et al., 1985) and in the serum of patients with breast cancer (Hayes et al., 1985; Hilkens et al., 1986; Burchell et al., 1984; Linsley et al., 1986; Papsidero et al., 1984b) . A number of these molecules are also related to the PAS-O glycoprotein found on the human milk fat globule and the epithelial membrane antigen (EMA) found in human milk (Shimizu et al., 1982; Ormerod et al., 1985) , which is not surprising since many of the antibodies which define these breast cancer associated antigens were originally produced against components of human milk Hilkens et al., 1984 (Burchell et al., 1983; Ormerod et al., 1983; Sekine et al., 1985) . Thirdly, the molecules are resistant to digestion by many commonly used proteases, but digestion by pronase and subtilisin, proteases which catalyse the hydrolysis of a wide variety of peptide bonds, have been reported Shimizu et al., 1982 (Burchell et al., 1983) . Likewise, antibody W5 bound more strongly to WI affinity-purified mucin from milk than to mucin purified from serum of breast cancer patients (Linsley et al., 1986 The heterogeneity seen with these high molecular weight glycoproteins indicates that they constitute a family of related molecules. Recent studies by other workers Ormerod et a4, 1985; Price et al., 1985 Price et al., , 1986 have shown that epitopes for a number of monoclonal antibodies reactive with high molecular weight glycoproteins of breast cancer are present on antigen preparations purified by monoclonal antibodies NCRC-11 and HMFG-2 respectively. In addition, antigen purified from human breast tumour cells and human milk by antibody DF3 has been shown to bind other monoclonal antibodies F36/22 and Cal (Abe et al., 1987) ; further evidence for a family of related high molecular weight tumour associated glycoproteins. In this study, antibodies DF3 and BC3 were shown to bind purified MSA, thereby confirming a relationship between MSA and the other high molecular weight glycoproteins of human milk and breast cancer. Antibody DF3 is now known to react with a core protein epitope (Siddiqui et al., 1988) and has been used to clone the same cDNA as was cloned by Gendler et al. (1988) using other antibodies (HMFG-1, HMFG-2 and SM-3). These data indicate that there is clearly a family of related molecules, each of which probably has the same core protein. Thus, it is possible that the 3E1.2 defined antigen (MSA) shares the same or similar core protein as DF3 defined antigen. It has been shown indirectly for the polymorphic epithelial mucin or PEM (Burchell et al., 1983) and directly for the DF3 purified antigen (Hull et al., 1988) that the glycosylation is different in normal (the carbohydrate component was analysed by Shimizu & Yamauchi (1982) ) and cancer associated mucin. Thus both core protein and carbohydrate epitopes can be identified on the cancer associated PEM mucin which are not found, or to a much lesser degree on the normally processed mucin as in HMFGM. It appears that oligosaccharide structures are important components of the 3E1.2 defined epitope which is closely tumour related. Determining the exact relationship of these molecules will involve further studies examining the primary polypeptide structure and oligosaccharide moieties of this group of molecules.
Polymorphism was also seen in the MSA molecules obtained from different patients (Figure 3) , as shown by the difference in mobilities of 3E1.2 reactive high molecular weight components in polyacrylamide gels. These differences could be due to either genetically determined allelic differences in the protein or carbohydrate portions of the molecules, or by the modification of sugar residues after cellular expression or secretion. In this context we note recent studies describing the genetic polymorphism of a urinary mucin-type glycoprotein related to the mucin glycoprotein of mammary tumours and human milk which defines a gene locus (PUM), with at least ten alleles which determine the expression of ten defined specificities Swallow et al., 1987) . In the light of the relationship between MSA and the high molecular weight glycoproteins of human milk, a similar system could control the expression of MSA.
In summary, this study has shown that monoclonal antibody 3E1.2 defines a high molecular weight glycoprotein (MSA) in the serum, ascites and breast cancer tissue of patients with breast cancer. The 3E1.2 defined antigen (MSA) appears to be related to a discrete family of high molecular weight glycoproteins defined in breast cancer patients sharing a number of common biochemical features and antigenic epitopes; however, monoclonal antibody 3E1.2 detects an epitope not expressed by PAS-O of human milk, making it a unique variant.
